These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 219366)

  • 1. Preliminary studies of sera and urine from patients with bladder cancer.
    Hollinshead AC
    Natl Cancer Inst Monogr; 1978 Dec; (49):193-7. PubMed ID: 219366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer.
    D'Hallewin MA; Baert L
    J Urol; 1996 Feb; 155(2):475-6. PubMed ID: 8558639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
    Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
    Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
    Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
    J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of the bladder tumor marker "Tu-MARK-BTA"].
    Yogi S; Ikeuchi T; Yoshikawa H; Hamashima T; Sasaki H; Morikawa F; Onodera Y; Matsumoto K; Kai Y
    Hinyokika Kiyo; 1991 Apr; 37(4):335-9. PubMed ID: 1891992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
    Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
    J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y; Okada Y; Terachi T; Yoshida O
    J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human bladder cancer associated antigens: evaluation of antigenicity in TCC tissues of different grades and in normal urothelium.
    Ben-Aïssa H; Paulie S; Gustafsson B; Håkansson L; Lagerkvist M; Gustafson H; Ahlstrand C; Perlmann P
    Anticancer Res; 1988; 8(3):443-9. PubMed ID: 3389746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer.
    Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT
    Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of antigens on transitional cell carcinoma with a xenogeneic antiserum.
    Bloom ET
    Natl Cancer Inst Monogr; 1978 Dec; (49):57-8. PubMed ID: 86168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
    el-Ahmady O; Halim AB; el-Din AG
    Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transitional cell cancer: fluorescent antibody binding to tumor cells in vitro.
    Elliott AY; Dombrovskis S; Fraley EE
    Natl Cancer Inst Monogr; 1978 Dec; (49):199-201. PubMed ID: 372820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transitional cell carcinoma: circulating tumor antigen correlated with presence/absence of tumor (leukocyte migration assay).
    Bowen JG
    Natl Cancer Inst Monogr; 1978 Dec; (49):245-7. PubMed ID: 748778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.